Cobimetinib Plus Vemurafenib: A Review in BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cobimetinib Plus Vemurafenib: A Review in BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma

Published:2016-03-16 Issue:5 Volume:76 Page:605-615
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Keating Gillian M.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-016-0562-7.pdf

Reference68 articles.

1. Dossett LA, Kudchadkar RR, Zager JS. BRAF and MEK inhibition in melanoma. Expert Opin Drug Saf. 2015;14(4):559–70.

2. Spagnolo F, Ghiorzo P, Queirolo P. Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget. 2014;5(21):10206–21.

3. Genentech USA Inc. Cotellic (cobimetinib) tablets, for oral use: US prescribing information. 2015. http://www.gene.com . Accessed 2 Feb 2016.

4. European Medicines Agency. Cotellic (cobimetinib): EU summary of product characteristics. 2015. http://ec.europa.eu . Accessed 2 Feb 2016.

5. Genentech USA Inc. Zelboraf® (vemurafenib) tablet for oral use: US prescribing information. 2015. http://www.gene.com . Accessed 2 Feb 2016.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FDA-approved small molecule kinase inhibitors for cancer treatment (2001–2015): Medical indication, structural optimization, and binding mode Part I;Bioorganic & Medicinal Chemistry;2024-09

2. Alternative Synthesis of Cobimetinib;Pharmaceutical Chemistry Journal;2024-04

3. Organocatalyzed diastereoselective cyclization of β-alkyl nitroolefins with alkylidene malononitriles: new approach to azetidine nitrones and isoxazoles;Organic Chemistry Frontiers;2024

4. p38 mitogen-activated protein kinase inhibitors;Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy;2024

5. Potential drug–drug interactions with mitogen-activated protein kinase (MEK) inhibitors used to treat melanoma;Expert Opinion on Drug Metabolism & Toxicology;2023-08-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3